With a pair of Phase III setbacks due to high placebo response, Relmada reports positive efficacy and safety data from an open-label trial while awaiting data from two ongoing pivotal studies for REL-1017, an NMDA antagonist.

CEO David Loew tells Scrip that valuations to do deals with biotechs “are now at a reasonable level [and] we are screening companies very actively as we speak."

Cash-strapped Nanobiotix has received a major boost with the news that J&J unit Janssen is paying $60m in upfront fees and R&D funding to license NBTXR3, which has the potential to enhance the efficacy of radiotherapy in multiple tumor types including head and neck cancer.

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb and Hannah Daniel discuss highlights from their DTA Summit coverage in Washington. Reed Miller talked to Frank Chan, the president of Medtronic’s Patient Monitoring, about plans for their patient monitoring as an independent company and Bayer AG’s new business unit focusing on digital health.